Oragenics IncOGEN
Price (close)
$0.50
Market cap
$2.3M
P/E
—
Revenue (TTM)
—
Net income
-$10.1M
Dividend yield
—
1-year total return
-60.7%
Net margin
—
Revenue growth
—
Debt / equity
—
What Oragenics Inc does.
description contains certain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially
from the results discussed in the forward-looking statements as a result of certain of the risks set forth herein. We assume no obligation
are a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $86,987 | $131,521 | $37,653 | — | — |
| Net income | -$26.4M | -$15.7M | -$14.3M | -$20.7M | -$10.6M | -$9.8M |
| Free cash flow | — | -$13.5M | -$15.4M | — | — | — |
More on OGEN.
- Oragenics Inc summary
- Oragenics Inc financial statements
- Oragenics Inc key metrics
- Oragenics Inc health scores and style box
- Oragenics Inc earnings
- Oragenics Inc dividends
- Oragenics Inc valuation
- Oragenics Inc ownership and insiders
- Oragenics Inc peers
Figures from Oragenics Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.